fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Regular screening of people at high risk for pancreatic cancer pays off

Written by | 20 Jul 2022

Surveillance programs for people at high risk of developing pancreatic cancers can help detect precancerous conditions and cancers early, when they are most treatable, according to a new… read more.

Leading radiotherapy researchers identify research priorities to improve outcomes for cancer patients

Written by | 19 Jul 2022

The NCRI Radiotherapy (CTRad) Group, a world-leading radiotherapy research group, has published its strategic priorities in radiotherapy research to address challenges in the field. The group has identified… read more.

Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma

Written by | 16 Jul 2022

A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma,… read more.

Adults with blood cancers respond to booster, not initial dose of COVID-19 vaccine

Written by | 13 Jul 2022

People with hematologic malignancies—or blood cancers including leukemia, lymphoma, and multiple myeloma—have an impaired immune system due to their disease and its treatment, putting them at risk of… read more.

Older adults with advanced bladder cancer prioritize honest information about what to expect

Written by | 11 Jul 2022

The median age for receiving a bladder cancer diagnosis is 73, and a significant number of those living with the disease are in their 70s and 80s. A longstanding stereotype… read more.

Bariatric surgery cuts cancer risks significantly

Written by | 8 Jul 2022

Obese adults who lost weight through bariatric surgery have achieved a significantly reduced risk of cancer and cancer-related death compared with obese adults who did not have such… read more.

Positive results from phase III PRIME study of Zejula at Society of Gynecologic Oncology Meeting – Zai Lab + GSK

Written by | 7 Jul 2022

Zai Lab Limited presented data from the Phase III PRIME study of Zejula (niraparib) as maintenance therapy at the Society of Gynecologic Oncology annual meeting . Zejula demonstrated… read more.

New guidance for cancer pain and opioid use disorder or opioid misuse

Written by | 6 Jul 2022

Opioids are a cornerstone of cancer pain management, but there is a lack of consensus on how to treat pain in cancer patients who also have struggled with… read more.

Dostarlimab effective in rectal cancer subset

Written by | 5 Jul 2022

PD-1 blockade with adjuvant dostarlimab in mismatch repair–deficient, locally advanced rectal cancer shows signs of high efficacy, researchers reported on June 5, 2022 in the NEJM/ New England… read more.

Researchers develop hybrid sensor that can help diagnose cancer

Written by | 3 Jul 2022

A team of researchers from HSE University, Skoltech, MPGU, and MISIS have developed a nanophotonic-microfluidic sensor whose potential applications include cancer detection, monitoring and treatment response assessment. Today,… read more.

App to help doctors help patients with leukemia

Written by | 28 Jun 2022

lymphocytic leukaemia (CLL) will develop a serious infection or need early treatment for CLL. 10 percent of these risk dying within a month. In order to help these… read more.

New approach to prostate cancer improves 5-year survival

Written by | 26 Jun 2022

A combination of hormone therapy and pelvic lymph node radiation improves survival of prostate cancer patients, researchers reported on May 26, 2022 in The Lancet. “We can now… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.